Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma

BACKGROUND: Salvage chemotherapy is the mainstay for the treatment of relapsed/refractory peripheral T-cell lymphomas (R/R PTCLs). ESHAP regimen, consisting of etoposide, methylprednisolone, high-dose Ara-C, and cisplatin is considered one of the well-accepted regimens for R/R lymphoma. Though, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Norasetthada, Lalita, Tantiworawit, Adisak, Rattanathammethee, Thanawat, Chai-Adisaksopha, Chatree, Chaipoh, Thanapat, Rattarittamrong, Ekarat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155849/
https://www.ncbi.nlm.nih.gov/pubmed/32300428
http://dx.doi.org/10.14740/jh459w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155849/
https://www.ncbi.nlm.nih.gov/pubmed/32300428
http://dx.doi.org/10.14740/jh459w

Ejemplares similares